文献速递类风湿关节炎系统性红斑狼疮其他结缔组织病

干扰素基因特征作为自身免疫性风湿病临床相关生物标志物

The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease.
PubMed 文献 · Lancet Rheumatol · 2021-11-17

干扰素基因特征(IGS)源于干扰素调节基因表达,随测序技术进步在风湿病中越来越多报道全血IGS升高。本文探讨升高的IGS作为临床相关生物标志物的潜在用途,包括诊断、治疗诊断、疾病活动度和临床特征预测,并指出其在不同疾病中预测方向不一致且计算方法缺乏标准化,IGS作为生物标志物值得进一步探索。

要点

  • 升高的IGS可在关节痛且抗环瓜氨酸蛋白抗体阳性患者中预测类风湿关节炎,或在抗核抗体阳性者中预测系统性红斑狼疮。
  • IGS可作为治疗诊断生物标志物,如预测类风湿关节炎患者对利妥昔单抗等疾病修饰治疗的反应。
  • 高IGS并非在所有疾病中一致预测更差临床表型,如原发性干燥综合征中疾病负担反而降低。

核心结论

  • IGS作为生物标志物值得进一步探索,预期在多种风湿病中具有有益的临床应用前景。

研究设计与样本

  • 本文为综述,探讨全血IGS作为临床相关生物标志物的作用,不涉及具体研究设计或样本量。

主要发现

  • 升高的IGS可在关节痛且抗环瓜氨酸蛋白抗体阳性患者中预测类风湿关节炎,或在抗核抗体阳性者中预测系统性红斑狼疮。
  • 升高的IGS可预测类风湿关节炎患者对利妥昔单抗等疾病修饰治疗的反应。
  • 升高的IGS可作为疾病活动度生物标志物(早期类风湿关节炎、皮肌炎、系统性硬化症、系统性红斑狼疮)。
  • 升高的IGS可预测临床特征,如系统性红斑狼疮中的狼疮肾炎或原发性干燥综合征中的疾病负担。
  • 高IGS并非在所有疾病中一致预测更差临床表型,如原发性干燥综合征中疾病负担降低;也非普遍预测所有治疗反应更差,如类风湿关节炎所示。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 高IGS并非在所有疾病中一致预测更差临床表型,如原发性干燥综合征中疾病负担降低,也非普遍预测所有治疗反应更差,如类风湿关节炎所示。
  • 当前缺乏计算IGS的标准化方法。
  • IGS作为生物标志物值得进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The interferon gene signature (IGS) is derived from the expression of interferon-regulated genes and is classically increased in response to type I interferon exposure. A raised whole blood IGS has increasingly been reported in rheumatic diseases as sequencing technology has advanced. Although its role remains unclear, we explore how a raised IGS can function as a clinically relevant biomarker, independent of whether it is a bystander effect or a key pathological process. For example, a raised IGS can act as a diagnostic biomarker when predicting rheumatoid arthritis in patients with arthralgia and anti-citrullinated protein antibodies, or predicting systemic lupus erythematous (SLE) in those with antinuclear antibodies; a theragnostic biomarker when predicting response for patients receiving disease modifying therapy, such as rituximab in rheumatoid arthritis; a biomarker of disease activity (early rheumatoid arthritis, dermatomyositis, systemic sclerosis, SLE); or finally a predictor of clinical characteristics, such as lupus nephritis in SLE or disease burden in primary Sjögren's syndrome. A high IGS does not uniformly predict worse clinical phenotypes across all diseases, as demonstrated by a reduced disease burden in primary Sjögren's syndrome, nor does it predict a universally poorer response to all therapies, as shown in rheumatoid arthritis. This dichotomy highlights both the complexity of type I interferon signalling in vivo and the current lack of standardisation when calculating the IGS. The IGS as a biomarker warrants further exploration, with beneficial clinical applications anticipated in multiple rheumatic diseases.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Cooles FAH, Isaacs JD. The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease. Lancet Rheumatol. 2021. PMID: 38288732. doi:10.1016/S2665-9913(21)00254-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。